Phase 1/2 first-in-human clinical study planned this year SHANGHAI and SAN DIEGO, May 22, 2025 /PRNewswire/ -- Duality Biotherapeutics ("DualityBio", HKEX:09606) partner Avenzo Therapeutics, Inc. ("Avenzo"), a clinical-stage biotechnology company developing next-generation oncology...
Hence then, the article about fda clearance of investigational new drug application received for novel egfr her3 bispecific antibody drug conjugate avzo 1418 db 1418 was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418 )
Also on site :
- 1968 Figure Skating Legend Won the Gold at 19 Years Old After Tragic Plane Crash Devastated Entire U.S. Team
- '90s One-Hit Wonder That Became a Worldwide Phenomenon Began a 14-Week Run at No. 1, 30 Years Ago Today
- Walmart's Vintage-Inspired Solar Lanterns Double as Planters, and You Can Snag a 2-Pack for Under $30